Open AccessA phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
Author(s) -
Keith W. Pratz,
Jason Kaplan,
Moshe Levy,
Dale Bixby,
Patrick W. Burke,
Harry P. Erba,
Trisha M. WiseDraper,
Gail J. Roboz,
Nikolaos Papadantonakis,
Trivikram Rajkhowa,
Daniela Hernandez,
Iwona Dobler,
Richard C. Gregory,
Cheryl Li,
Shining Wang,
Kate Stumpo,
Karuppiah Kannan,
Harry Miao,
Mark J. Levis
Publication year - 2022
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2022.281216
Subject(s) - medicine , syk , tolerability , regimen , refractory (planetary science) , dosing , myeloid leukemia , gastroenterology , tyrosine kinase inhibitor , adverse effect , pharmacology , tyrosine kinase , cancer , physics , receptor , astrobiology